| Bioactivity | Zilovertamab vedotin (VLS-101) is a novel antibody-drug conjugate comprising the humanized monoclonal antibody zilovertamab and and the anti-microtubule cytotoxin monomethyl vedotin. Zilovertamab vedotin binding to tumor cell ROR1 results in rapid internalization, trafficking to lysosomes, antibody–drug conjugate cleavage, and monomethyl vedotin release. Zilovertamab vedotin induces apoptosis. Zilovertamab vedotin can be used in research of cancer[1]. |
| Invitro | Zilovertamab vedotin (VLS-101; 0-100 μg/mL) 以剂量依赖方式诱导 ROR1+ 原代 MCL 细胞的细胞毒性[1]。Zilovertamab vedotin (24h; ibrutinib 敏感 (JeKo-1) 和耐药 (JeKo BTK kd2) 细胞株) 诱导细胞凋亡和细胞周期阻滞在 G2/M 期[1]。 |
| Name | Zilovertamab vedotin |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |